Alvimedica Tibbi Urunler Sanayi VE Dis Ticaret A.S
Developer and manufacturer of minimally-invasive interventional cardiology and endovascular devices. The company designs polymer-free drug-eluting stents, balloon and catheter technologies and operates manufacturing sites in Europe and Turkey. It engages in clinical research (multiple randomized trials), regulatory compliance (CE and FDA approvals reported), and collaborative R&D with physicians and external partners.
Industries
Nr. of Employees
medium (51-250)
Alvimedica Tibbi Urunler Sanayi VE Dis Ticaret A.S
Ferhatpaşa Mah. Tahta Köprü Sok. No:25/A Çatalca, İstanbul, Turkey
Products
Polymer-free amphilimus-eluting coronary stent
Coronary drug-eluting stent using polymer-free abluminal reservoir drug delivery and a sirolimus+fatty-acid formulation to enhance vessel-wall drug uptake.
Polymer-free amphilimus-eluting below-the-knee (BTK) stent
Balloon-expandable stent for below-the-knee arteries using abluminal reservoir drug elution and formulations aimed at improved efficacy in diabetic patients.
Self-expanding nitinol drug-eluting stent for SFA
Self-expanding nitinol stent platform for superficial femoral artery lesions with drug-eluting properties for peripheral use.
Guiding and diagnostic catheters with radial curve options
Diagnostic and guiding catheters designed with braided shafts and dedicated radial curve geometries to improve torque, stability and deliverability for trans-radial access.
Balloon catheters (including non-compliant balloons)
Range of balloon catheters for percutaneous interventions including non-compliant balloon devices intended for precise lumen expansion.
Polymer-free amphilimus-eluting coronary stent
Coronary drug-eluting stent using polymer-free abluminal reservoir drug delivery and a sirolimus+fatty-acid formulation to enhance vessel-wall drug uptake.
Polymer-free amphilimus-eluting below-the-knee (BTK) stent
Balloon-expandable stent for below-the-knee arteries using abluminal reservoir drug elution and formulations aimed at improved efficacy in diabetic patients.
Self-expanding nitinol drug-eluting stent for SFA
Self-expanding nitinol stent platform for superficial femoral artery lesions with drug-eluting properties for peripheral use.
Guiding and diagnostic catheters with radial curve options
Diagnostic and guiding catheters designed with braided shafts and dedicated radial curve geometries to improve torque, stability and deliverability for trans-radial access.
Balloon catheters (including non-compliant balloons)
Range of balloon catheters for percutaneous interventions including non-compliant balloon devices intended for precise lumen expansion.
Services
Partnership model for external innovators and physicians to co-develop interventional devices and process innovations; accepts project submissions for industrial collaboration.
Manufacturing and assembly capability for interventional cardiology and endovascular devices at facilities in Italy and Turkey with documented quality systems.
Partnership model for external innovators and physicians to co-develop interventional devices and process innovations; accepts project submissions for industrial collaboration.
Manufacturing and assembly capability for interventional cardiology and endovascular devices at facilities in Italy and Turkey with documented quality systems.
Expertise Areas
- Interventional cardiology device development
- Endovascular device development
- Polymer-free drug-eluting stent technologies
- Peripheral vascular stent systems
Key Technologies
- Polymer-free drug-eluting stents
- Abluminal reservoir drug delivery
- Sirolimus-based fatty-acid-enhanced formulations
- Endothelialization-promoting surface coatings
News & Updates
Attendance and participation in EuroPCR 2024 (interventional cardiology conference).
Attendance at the Leipzig Interventional Course (LINC) 2024.
Launch of new radial diagnostic catheter curves following CE marking to improve trans-radial diagnostic procedures.
Report of randomized trial results showing a polymer-free amphilimus-eluting stent reduced target lesion failure at one year versus comparator in patients with diabetes.
CE marking reported for diagnostic catheters and multiple stent families (including polymer-free and nitinol DES).
Opened a new plant in Çatalca with a stated 1,000,000 DES capacity (7,500 m2).
Attendance and participation in EuroPCR 2024 (interventional cardiology conference).
Attendance at the Leipzig Interventional Course (LINC) 2024.
Launch of new radial diagnostic catheter curves following CE marking to improve trans-radial diagnostic procedures.
Report of randomized trial results showing a polymer-free amphilimus-eluting stent reduced target lesion failure at one year versus comparator in patients with diabetes.
CE marking reported for diagnostic catheters and multiple stent families (including polymer-free and nitinol DES).
Opened a new plant in Çatalca with a stated 1,000,000 DES capacity (7,500 m2).